The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 16, 2015

Filed:

Aug. 03, 2010
Applicants:

Vitezslav Bryja, Brno, CZ;

Pavel Krejci, Nove Mesto na Morave, CZ;

Marketa Kaucka, Hradec Kralove, CZ;

Sarka Pospisilova, Brno, CZ;

Jiri Mayer, Brno, CZ;

Alois Kozubik, Brno, CZ;

Karla Plevova, Hostalkova u Vsetina, CZ;

Jana Kotaskova, Brno, CZ;

Inventors:

Vitezslav Bryja, Brno, CZ;

Pavel Krejci, Nove Mesto na Morave, CZ;

Marketa Kaucka, Hradec Kralove, CZ;

Sarka Pospisilova, Brno, CZ;

Jiri Mayer, Brno, CZ;

Alois Kozubik, Brno, CZ;

Karla Plevova, Hostalkova u Vsetina, CZ;

Jana Kotaskova, Brno, CZ;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/68 (2006.01); G01N 33/574 (2006.01); G01N 33/577 (2006.01); C12Q 1/68 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/5052 (2013.01); G01N 33/6842 (2013.01); G01N 33/5091 (2013.01); G01N 33/577 (2013.01); G01N 33/57426 (2013.01); C12Q 2600/118 (2013.01);
Abstract

The invention provides a method of determination of diagnosis and prognosis of B-cell chronic lymphocytic leukemia from a biological sample collected from the body of a patient, wherein the status of Wnt/PCP signaling pathway is determined. Within the framework of the present invention the relation of CLL and molecular signaling pathway Wnt/PCP the components of which are markedly up-regulated in B-lymphocytes of the patients suffering from CLL was identified. The status of the Wnt/PCP signaling pathway can be determined, e.g., by the determination of the expression of components of said signaling pathway or by the determination of migration of CLL cells in the gradient of a chemokine in the presence of the ligand of said signaling pathway. The invention also relates to suitable oligonucleotides for use in the method of determination of expression of the signaling pathway components.


Find Patent Forward Citations

Loading…